Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Increase in share capital following exercise of warrants – Notice of changes in share capital and voting rights pursuant to section 32 of the Danish Capital Markets Act | ||
| By: GlobeNewswire - 08 Apr 2021 | Back to overview list |
|
April 8, 2021 Increase in share capital following exercise of warrants – Notice of changes in share capital and voting rights pursuant to section 32 of the Danish Capital Markets Act The Company’s share capital has been increased by normally DKK 1,172,500, corresponding to 1,172,500 new shares, as a result of exercise of warrants issued under the Company’s incentive warrant program. Total proceeds from the capital increase amount to approximately DKK 4.4 million. After the share capital increase, the Company’s share capital amounts to nominally DKK 267,754,404 divided into 267,754,404 shares each carrying 1 voting right, corresponding to a total of 267,754,404 voting rights, cf. section 32 of the Danish Capital Markets Act. Amended Articles of Association reflecting the above are available on the Company’s website. For further information, please contact: Ole Larsen, CFO Telephone +45 4529 0000, e-mail: investor@bioporto.com About BioPorto BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR]. Attachment |
||
|
||
 | Back to overview list | |